Trust Co. of Virginia VA Has $19.27 Million Stake in Eli Lilly and Company (NYSE:LLY)

Trust Co. of Virginia VA reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,774 shares of the company’s stock after selling 474 shares during the period. Eli Lilly and Company accounts for approximately 1.8% of Trust Co. of Virginia VA’s investment portfolio, making the stock its 13th biggest position. Trust Co. of Virginia VA’s holdings in Eli Lilly and Company were worth $19,273,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Trexquant Investment LP bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $3,874,000. Morningstar Investment Services LLC raised its stake in Eli Lilly and Company by 112.8% during the third quarter. Morningstar Investment Services LLC now owns 1,741 shares of the company’s stock worth $948,000 after buying an additional 923 shares during the last quarter. Ancora Advisors LLC lifted its holdings in Eli Lilly and Company by 2.9% in the third quarter. Ancora Advisors LLC now owns 6,935 shares of the company’s stock valued at $3,725,000 after buying an additional 198 shares during the period. Gotham Asset Management LLC boosted its position in Eli Lilly and Company by 111.3% during the third quarter. Gotham Asset Management LLC now owns 7,386 shares of the company’s stock valued at $3,967,000 after acquiring an additional 3,891 shares during the last quarter. Finally, Kinloch Capital LLC grew its holdings in Eli Lilly and Company by 25.8% during the 3rd quarter. Kinloch Capital LLC now owns 717 shares of the company’s stock worth $385,000 after acquiring an additional 147 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.4 %

LLY stock opened at $905.38 on Friday. The firm has a market capitalization of $860.48 billion, a PE ratio of 133.34, a P/E/G ratio of 1.97 and a beta of 0.36. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $915.54. The stock’s 50 day moving average is $814.40 and its 200-day moving average is $739.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s revenue was up 26.0% on a year-over-year basis. During the same period last year, the business earned $1.62 EPS. Sell-side analysts expect that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Truist Financial reissued a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, June 24th. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $812.72.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 17,229 shares of Eli Lilly and Company stock in a transaction on Monday, June 24th. The stock was sold at an average price of $902.38, for a total value of $15,547,105.02. Following the sale, the insider now owns 97,556,910 shares in the company, valued at $88,033,404,445.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 789,704 shares of company stock valued at $672,385,964. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.